Abstract: A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient. The formulation has the following quali-quantitative composition by weight: (a) cyclosporin in the amount of from about 8 to about 12% of the total weight; (b) ethanol in the amount of from about 12 to about 18% of the total weight; (c) a polyoxyethylene/polyoxypropylene block copolymer in the amount of from about 8 to about 12% of the total weight; (d) water in the amount of from about 4 to about 6% of the total weight; (e) a solubilizer having an HLB from 13 to 15 in the amount of from about 28 to about 40% of the total weight; (f) an ester of a C1-C6 alkyl alcohol and a C14-C18 saturated fatty acid in the amount of from about 20 to about 30% of the total weight.